|Bid||178.50 x 800|
|Ask||179.22 x 900|
|Day's range||149.12 - 175.89|
|52-week range||6.77 - 331.68|
|Beta (5Y monthly)||1.58|
|PE ratio (TTM)||N/A|
|Earnings date||01 Mar 2021|
|Forward dividend & yield||N/A (N/A)|
|1y target est||281.25|
Novavax (NASDAQ: NVAX) reached an agreement to sell 1.1 million doses of its coronavirus vaccine to COVAX, an organization led by the Coalition of Epidemic Preparedness Innovations, Gavi, and the World Health Organization. In this video from Motley Fool Live, recorded on Feb. 22, Fool.com contributors Brian Orelli and Keith Speights discuss the deal and the prospects for Novavax's vaccine.
In this Motley Fool Live video recorded on Feb. 24, 2021, Fool.com contributors Keith Speights and Brian Orelli discuss which COVID-19 vaccine stocks are the best picks for aggressive and conservative investors. Keith Speights: We basically have six leaders or potential leaders in the U.S. COVID-19 vaccine space. There's Pfizer (NYSE: PFE), of course, along with its partner BioNTech (NASDAQ: BNTX), ticker there's BNTX, there's Moderna (NASDAQ: MRNA), ticker there's MRNA, Johnson & Johnson (NYSE: JNJ), JNJ is the ticker there, Novavax (NASDAQ: NVAX), NVAX is the ticker, and AstraZeneca (NASDAQ: AZN), AZN is the ticker there.
The B1351 coronavirus variant from South Africa poses a threat to the currently authorized vaccines from Moderna (NASDAQ: MRNA) and BioNTech (NASDAQ: BNTX)/Pfizer (NYSE: PFE) because they weren't specifically designed to protect against that variant. In this video from Motley Fool Live, recorded on Feb. 22, Fool.com contributors Brian Orelli and Keith Speights discuss the ins and outs of the vaccines' potential to protect against the variants and what the companies are doing to deal with the new challenge. Brian Orelli: We got some data last week published in the New England Journal of Medicine on the coronavirus vaccines protecting against the South African variant -- that's the B1351 -- by Pfizer and BioNTech vaccine, the neutralization was weaker by about two-thirds.